Compare Bristol-Myers Squibb Co (BMY) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Hasbro, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $116.30B), while Hasbro, Inc. trades at $79 (market cap $11.10B). The key difference: Bristol-Myers Squibb Co is far larger — about 10.5× Hasbro, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | HAS | |
|---|---|---|
Market Cap | $116.30B | $11.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $105.88 |
52-Week Low | $42.60 | $70.95 |
Enterprise Value | $152.24B | $13.37B |
Dividend Yield | 4.42% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Hasbro (HAS) trades at $79.53, showing modest daily gains but facing bearish technical signals. The company reported negative net income of -$322.4M in 2025 despite revenue growth to $4.7B, with profitability metrics showing strain. Recent earnings beats provide some optimism, while analyst consensus remains positive with a $104 price target representing 31% upside potential from current levels.
Investment outlook balances strong analyst support against fundamental challenges. The stock offers significant upside if management can improve profitability, but faces headwinds from negative margins and high debt levels. Key catalysts include Q2 2026 earnings on July 21 and execution of the company's 'aging up' strategy targeting adult consumers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
